Trial Profile
HepaStem Long-Term Safety Registry - Registry for Patients Who Have Been Administered HepaStem
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Crigler-Najjar syndrome; Inborn urea cycle disorders; Liver disorders; Liver failure
- Focus Adverse reactions
- Acronyms PROLONGSTEM
- Sponsors Promethera Biosciences
- 31 Dec 2021 Planned End Date changed from 1 Jul 2023 to 1 Jul 2028.
- 31 Dec 2021 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2028.
- 23 May 2019 Status changed from not yet recruiting to recruiting.